Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.3252W HIGH $4.71
Volume
1.24 M
Value Traded
767.15 K
Short % Float
8.38%
Days to Cover
7.9
-20.26%Week
-53.38%1 Month
-68.31%3 Month
-82.12%6 Month
-92.64%5 Year
-90.95%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
24.03 M
EPS (TTM)
-1.15
P/E Ratio
-
Ent. Value
76.29 M
Total Shares
78.59 M
Float Shares
72.79 M
Insiders
7.37%
Institutions
12.19%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
NNOX Catalyst Timeline
Dated clinical, regulatory and corporate events for NANO-X IMAGING LTD
Past FDA Catalysts and PDUFA Decisions
How NNOX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
NANO-X IMAGING LTD is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every NNOX program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Meltzer ErezDirector, Officer (Chief Executive Officer) | Buy | 25,000 90,443 held | $0.45 | 10/19/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NNOX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in NNOX for Q2 2026. | ||||
NNOX Institutional Ownership Trends
NNOX Short Interest
Shares sold short, counted twice a month.
8.38%
Short % of Float
of tradable shares sold short
6.1M
Shares Sold Short
-3.2% vs prior count
7.9 High
Days to Cover
trading days of normal volume to buy every short share back
774.1K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NNOX ranks across every disease it competes in
Competitive Position is a premium feature
See how NNOX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNNOX News
NNOX▼ -9.5%on this news
Nanox Provides Business Update and Furnishes Certain Preliminary Unaudited Financial Data for Third Quarter Ended September 30, 2026
Nanox Imaging Ltd. provided a business update and preliminary financial data for Q3 2026. The company reported expected revenue of approximately $4.3 to $4.4 million, an increase from $3.4 million in Q3 2025. However, cash reserves have dropped significantly, raising concerns about the company's ability to sustain operations in the coming year.
Read more →NNOX▼ -7.8%on this news· ran to -22% by day 3shared move
Nanox AI Ltd. Enters into Distribution Agreement with Technologic s.r.l., an Affiliate of Tecnologie Avanzate, to Commercialize Nanox.AI Bone Solution in Italy
Nanox AI Ltd. has signed a distribution agreement with Technologic s.r.l. to market its HealthOST solution in Italy. This partnership aims to utilize Technologic's extensive experience in the medical technology sector to enhance the commercial reach of the AI-powered bone health assessment tool. The agreement is expected to improve patient care by facilitating early detection of musculoskeletal diseases.
Read more →NNOXNanox Selected as One of TIME’s Best Inventions of 2026 for its Nanox.ARC X
Nanox Imaging Ltd. announced that its Nanox.ARC X has been named one of TIME's Best Inventions of 2026. This recognition marks Nanox's second appearance on the list and highlights the system's ability to provide advanced medical imaging with reduced radiation. The Nanox.ARC X is designed for easy deployment in various healthcare settings.
Read more →NNOX▼ -6.4%on this news
Nanox Expands Latin American Presence with Nanox.ARC Distribution Agreement in Costa Rica
Nanox Imaging Ltd. has signed a distribution agreement with SOLME RC, S.A. to market the Nanox.ARC in Costa Rica. This marks the third Latin American market for Nanox this year, following Argentina and Peru. SOLME will handle marketing, installation, and support for the Nanox.ARC, which aims to enhance access to 3D medical imaging in the country.
Read more →NNOX▼ -16.2%on this newsshared move
Nanox Announces Second Quarter 2026 Financial Results and Provides Business Updates
Nanox Imaging Ltd (NNOX) reported Q2 2026 revenues of $4.2 million, a 37% increase from the previous year. The company expanded its U.S. distribution and launched its first imaging network site. However, it faced a significant GAAP net loss of $55.5 million and recorded a $40.7 million impairment charge.
Read more →NNOX▲ +16.4%on this news· ran to +31% by day 1shared move
Nanox Signs Distribution Agreement with Associated X-Ray Imaging to Expand Nanox.ARC Adoption Across New England
Nano-X Imaging signed a distribution deal with Associated X-Ray Imaging to deploy its Nanox.ARC system in New England. The agreement leverages the partner's regional infrastructure to expand access to the FDA-cleared 3D tomosynthesis device. This move supports Nanox's U.S. commercial strategy by targeting outpatient and community clinics. CEO Erez Meltzer cited the partner's local expertise as key to measured adoption.
Read more →NNOXNanox to Report Second Quarter 2026 Financial Results on September 9, 2026
Nanox Imaging Ltd. will announce its financial results for Q2 2026 on September 9, 2026. CEO Erez Meltzer and CFO Guy Nathanzon will host a conference call at 8:30 a.m. ET to discuss the results and provide a business update. The company continues to focus on enhancing preventive healthcare through innovative imaging technology.
Read more →NNOX▼ -5%on this news
Nanox and Vertec Scientific Enter Exclusive Sales Reseller Agreement for the Commercialization of Nanox.AI Bone Solution (HealthOST) in the United Kingdom
Nanox Imaging announced an exclusive sales reseller agreement with Vertec Scientific for the commercialization of its AI bone solution, HealthOST, in the UK. The agreement, effective for three years, includes minimum annual license commitments. HealthOST, which analyzes routine CT scans for musculoskeletal diseases, aims to enhance early detection and preventive care.
Read more →NNOXNanox.AI Optimizes Medical Imaging AI Application Framework for Intel Core Ultra Processors with OpenVINO
Nanox.AI has optimized its medical imaging AI framework for Intel Core Ultra processors using OpenVINO. This enhancement allows healthcare organizations to run AI applications on-premise, improving efficiency and data control. The framework aims to help identify chronic conditions from existing CT scans, supporting preventive care management.
Read more →NNOXNano-X Imaging Ltd. Announces Pricing of a $8 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Nano-X Imaging Ltd. has announced a registered direct offering priced at $1.00 per share, aiming to raise approximately $8 million. The offering involves 8 million ordinary shares and warrants, with proceeds intended for working capital. The closing is expected on August 7, 2026, subject to customary conditions. A.G.P./Alliance Global Partners is the placement agent for this transaction.
Read more →NNOXExclusive distribution agreement marks Nanox’s entry into the Peruvian market
Nanox Imaging Ltd. has signed an exclusive distribution agreement with Top Med SAC to deploy its Nanox.ARC system in Peru. The initial deployment will include six systems under a capex model, with Top Med responsible for regulatory approvals and support. This agreement aims to enhance access to diagnostic imaging services in Peru, addressing regional disparities.
Read more →NNOX▲ +8.1%on this news
Nanox Announces Distribution Agreement with NuvioDx to Support Deployment of Nanox.ARC Systems
Nanox Imaging Ltd. has signed a distribution agreement with NuvioDx to enhance the deployment of its Nanox.ARC systems across the U.S. This partnership aims to expand access to advanced diagnostic imaging technologies. The Nanox.ARC system is noted for its cost-effectiveness and reduced radiation exposure compared to traditional methods.
Read more →NNOX▼ -24.4%on this news· ran to -40% by day 3shared move
Nanox Announces Fourth Quarter of 2025 Financial Results and provides Business Updates
Nanox Imaging Ltd. has announced its financial results for Q4 of 2025, revealing a net loss of $33.4 million, an increase from last year's loss of $14.1 million. The company is advancing its commercialization efforts in the U.S., having signed several distribution agreements for its Nanox.ARC systems. Additionally, Nanox has integrated Nanox Health IT and appointed a new CFO with significant experience, aiming for a seamless financial transition. Despite the operational progress, the significant losses and asset impairment have raised concerns about its fiscal health.
Read more →NNOXNanox Signs Distribution Agreement with Digital X-Ray Imaging to Expand Nanox.ARC Adoption in Arkansas
Nanox Imaging Ltd. has signed a distribution agreement with Digital X-Ray Imaging to promote the Nanox.ARC system in Arkansas. This partnership aims to enhance the adoption of advanced 3D imaging technology in various healthcare settings. The agreement marks the fourth such collaboration in 2026, reflecting Nanox's growing commercial momentum in the U.S. market.
Read more →NNOX▲ +5.3%on this news
Nanox Signs Distribution Agreement with Imperial Imaging Technology to Expand Nanox.ARC Access Across U.S. Southeast
Nanox Imaging Ltd. has signed a distribution agreement with Imperial Imaging Technology to enhance the rollout of its Nanox.ARC imaging system across six southeastern U.S. states. This partnership aims to improve access to advanced musculoskeletal imaging in orthopedic practices, reducing patient travel and administrative burdens. The agreement aligns with Nanox's strategy to expand its distribution network in key markets.
Read more →NNOXNanox to Showcase Nanox.ARC Live in Europe for First Time and Present New AI Capabilities at ECR 2026
Nanox Imaging Ltd. will debut its Nanox.ARC digital tomosynthesis system in Europe at ECR 2026, showcasing new AI capabilities. The system is designed for enhanced 3D imaging with lower costs and radiation doses. Live demonstrations and clinical data presentations will highlight its role in lung cancer screening and other applications. The event marks a significant step in Nanox's European market expansion.
Read more →NNOX▼ -6.3%on this news
Nanox Receives FDA 510(k) Clearance for TAP2D New Image Enhancement Capability for Nanox.ARC and Nanox.ARC X Systems
Nanox Imaging Ltd. has received FDA 510(k) clearance for its TAP2D image enhancement capability, which allows radiologists to generate a 2D image from a tomosynthesis scan. This development aims to position Nanox's systems as primary diagnostic tools in the U.S. market, enhancing access to innovative medical imaging solutions. The new feature is designed to streamline workflow for healthcare professionals.
Read more →NNOXNanox Expands in Europe with New Nanox.ARC Distribution Engagement in Serbia, Montenegro, and Bosnia and Herzegovina
Nanox Imaging Ltd. has announced a collaboration with Adriamed to distribute its Nanox.ARC imaging system in Serbia, Montenegro, and Bosnia and Herzegovina. This partnership aims to enhance access to advanced medical imaging solutions in the Western Balkans, leveraging Adriamed's regional expertise. The Nanox.ARC system is CE Mark certified, allowing for commercialization across Europe.
Read more →NNOX▼ -5.3%on this news
Nanox Announces $15 Million Registered Direct Offering of Common Stock
Nanox Imaging Ltd. has announced a registered direct offering of 3,826,530 ordinary shares, expected to raise approximately $15 million before expenses. The proceeds will primarily support working capital and general corporate purposes while bolstering the company's balance sheet. This move is aimed at advancing the company's technologies, market expansion, and AI infrastructure, as highlighted by CEO Erez Meltzer. The closing of the offering is scheduled for approximately November 25, 2025, pending customary conditions.
Read more →NNOX▲ +13.9%on this news· ran to +49% by day 3shared move
Nanox Announces Third Quarter of 2025 Financial Provides Business Update
Nanox Imaging Ltd (NASDAQ: NNOX) reported its third quarter 2025 financial results, showing a slight increase in net loss to $13.7 million from $13.6 million in Q3 2024. Revenue grew to $3.4 million, driven primarily by teleradiology services, which represented a strong performance with improved gross profit margins. Despite achieving some positive operational metrics, the company experienced significant cash burn, leading to negative cash flow of $30.4 million. Looking ahead, Nanox aims to deploy over 100 imaging systems worldwide by year-end 2025.
Read more →About NANO-X IMAGING LTD
BIOPHARMAWATCH ELITE PLUS
Trade the next NNOX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime